Low gamma-butyrobetaine dioxygenase (BBOX1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma: a machine learning approachopen access
- Authors
- Kim, Kyu-Shik; Moon, Kyoung Min; Min, Kyueng-Whan; Jung, Woon Yong; Shin, Su-Jin; Lee, Seung Wook; Kwon, Mi Jung; Kim, Dong-Hoon; Oh, Sukjoong; Noh, Yung-Kyun
- Issue Date
- May-2023
- Publisher
- WILEY
- Keywords
- renal cell carcinoma; machine learning; low gamma-butyrobetaine dioxygenase; CD8+ T cells
- Citation
- JOURNAL OF PATHOLOGY CLINICAL RESEARCH, v.9, no.3, pp.236 - 248
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF PATHOLOGY CLINICAL RESEARCH
- Volume
- 9
- Number
- 3
- Start Page
- 236
- End Page
- 248
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/186054
- DOI
- 10.1002/cjp2.315
- ISSN
- 2056-4538
- Abstract
- Gamma-butyrobetaine dioxygenase (BBOX1) is a catalyst for the conversion of gamma-butyrobetaine to l-carnitine, which is detected in normal renal tubules. The purpose of this study was to analyze the prognosis, immune response, and genetic alterations associated with low BBOX1 expression in patients with clear cell renal cell carcinoma (RCC). We analyzed the relative influence of BBOX1 on survival using machine learning and investigated drugs that can inhibit renal cancer cells with low BBOX1 expression. We analyzed clinicopathologic factors, survival rates, immune profiles, and gene sets according to BBOX1 expression in a total of 857 patients with kidney cancer from the Hanyang University Hospital cohort (247 cases) and The Cancer Genome Atlas (610 cases). We employed immunohistochemical staining, gene set enrichment analysis, in silico cytometry, pathway network analyses, in vitro drug screening, and gradient boosting machines. BBOX1 expression in RCC was decreased compared with that in normal tissues. Low BBOX1 expression was associated with poor prognosis, decreased CD8+ T cells, and increased neutrophils. In gene set enrichment analyses, low BBOX1 expression was related to gene sets with oncogenic activity and a weak immune response. In pathway network analysis, BBOX1 was linked to regulation of various T cells and programmed death-ligand 1. In vitro drug screening showed that midostaurin, BAY-61-3606, GSK690693, and linifanib inhibited the growth of RCC cells with low BBOX1 expression. Low BBOX1 expression in patients with RCC is related to short survival time and reduced CD8+ T cells; midostaurin, among other drugs, may have enhanced therapeutic effects in this context.
- Files in This Item
-
- Appears in
Collections - 서울 공과대학 > 서울 컴퓨터소프트웨어학부 > 1. Journal Articles
- 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
- 서울 의과대학 > 서울 병리학교실 > 1. Journal Articles
- 서울 의과대학 > 서울 비뇨의학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/186054)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.